STAT3 is activated in response to various cytokines and growth factors including IFNγ, IL-6 and OSM. The activation of STAT3 results in formation of STAT3 homodimers and STAT3/STAT1 heterodimers that translocate to the cell nucleus and induce transcription of genes by binding to the consensus element on the promoter region of target genes associated with cell growth and apoptosis. Signosis has established Stat3 luciferase reporter HeLa stable cell line, which can be used as a reporter system for monitoring the activation of Stat3 triggered by stimuli treatment, enforced gene expression and gene knockdown.
The cell line was established by transfection using a pTA-Stat3-luciferase reporter vector, which contains 4 repeats of Stat3 binding sites, a minimal promoter upstream of the firefly luciferase coding region, along with hygromycin expression vector followed by hygromycin selection. The hygromycin resistant clones were subsequently screened for oncostatin induced luciferase activity. The clone with the highest fold induction (10 fold) was selected and expanded to produce this stable cell line.
Principle behind TF luciferase reporter. TF luciferase reporter stable cell line utilizes artificial promoter constructs to drive luciferase expression. The promoter region can consists of multiple repeats of a cis-element TF binding site, a DNA fragment from the promoter region of a known TF downstream gene, or a DNA fragment containing putative/known TF binding sites. There are several ways that a TF can be activated, such as through extracellular stimuli or through intracellular signaling pathways. Once activated, the TF translocates to the nucleus and often interacts with relevant co-factors to drive gene expression. Once luciferase is expressed, it can generate light in an enzymatic assay and the amount of light measured is positively correlated with the level of TF activation. |
Analysis of HeLa/STAT3-luciferase activity of control and treatment with Oncostatin. The cells were seeded on a 96-well plate for overnight with DMEM including 10% FBS. The cells then were treated with or without 10ng/ml Oncostatin respectively in DMEM and 0.1% FBS for 8 hours. Stat3 luciferase reporter cell line showed more than 25-fold increase in luciferase activity in response to Oncostatin M treatment.
Signosis
Signosis提供一种分子工具的公司,研发独特的产品用于生命科学研究,临床和药物发现研究领域中生物标志物的发现和分析。
Signosis is a leader of bioassay provider over a decade, dedicated to the development and commercialization of plate-based analysis products in the life sciences community. We focus on many regulatory key molecules: transcription factors, cytokines, miRNAs, and disease markers. Our mission is to provide excellent products and service worldwide, which include scientists in pharmaceutical companies and biotech industry, academic and research institutes in many countries. We object to develop innovative assay products with high sensitivity, high throughput and cost-effectiveness.
产品列表:
No. | 品牌 | 货号 | 名称 | 规格 |
1 | Signosis | p300 Microplate Snapshot ChIP Assay | ||
2 | Signosis | Human NFκB-Regulated cDNA Plate Array | ||
3 | Signosis | Human miRNA Array I | ||
4 | Signosis | Snapshot ChIP Assay | ||
5 | Signosis | OCT4 Snapshot ChIP Assay | ||
6 | Signosis | Microplate Snapshot ChIP Assay | ||
7 | Signosis | NRF2 Microplate Snapshot ChIP Assay | ||
8 | Signosis | SMAD Microplate Snapshot ChIP Assay | ||
9 | Signosis | NFkB Microplate Snapshot ChIP Assay | ||
10 | Signosis | H3 Microplate Snapshot ChIP Assay | ||
11 | Signosis | Human NFκB-Regulated cDNA Profiling in Cell Lysates | ||
12 | Signosis | Human Apoptosis cDNA Plate Array I | ||
13 | Signosis | AP2 EMSA Kit | ||
14 | Signosis | NRF2 Snapshot ChIP Assay | ||
15 | Signosis | FA-0004 | AP1 Filter Plate Assay |